VEA
LYEL icon

Virtus ETF Advisers’s Lyell Immunopharma LYEL Stock Holding History

Virtus ETF Advisers’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,779
Closed -$49.1K – 489
2024
Q3 		$49.1K Buy
1,779
+31
+2% +$911 0.02% 442
2024
Q2 		$50.7K Sell
1,748
-397
-19% -$18.9K 0.02% 443
2024
Q1 		$95.6K Sell
2,145
-147
-6% -$6.29K 0.05% 371
2023
Q4 		$88.9K Buy
2,292
+859
+60% +$30.9K 0.06% 406
2023
Q3 		$42.1K Sell
1,433
-143
-9% -$6.79K 0.03% 420
2023
Q2 		$100K Buy
1,576
+155
+11% +$8.58K 0.06% 379
2023
Q1 		$67.1K Sell
1,421
-546
-28% -$29.2K 0.04% 405
2022
Q4 		$137K Buy
1,967
+811
+70% +$80.6K 0.07% 375
2022
Q3 		$169K Buy
1,156
+9
+0.8% +$1.22K 0.07% 336
2022
Q2 		$150K Buy
+1,147
New +$117K 0.06% 318

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Virtus ETF Advisers's LYEL Position: Q4 2024 in Review

Virtus ETF Advisers sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 1,779 shares — an estimated $49.1K sold.

Virtus ETF Advisers first reported a position in LYEL in Q2 2022 and held it in 10 quarters. The position peaked at $169K in Q3 2022. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Virtus ETF Advisers reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,779 Lyell Immunopharma shares in Q4 2024, an estimated $49.1K.
  • Virtus ETF Advisers first reported a position in Lyell Immunopharma in Q2 2022 and held it in 10 quarters.
  • Virtus ETF Advisers's Lyell Immunopharma position peaked at $169K in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.